Company intelligence / Profile preview

Nuage Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Nuage Therapeutics has developed a proprietary drug discovery platform that enables the targeting of intrinsically disordered proteins—previously considered undruggable. Their lead programs are in preclinical development and focus on oncogenic transcription factors implicated in challenging cancers. The company raised €12 million in seed funding to advance these programs.

Therapeutic areas: Oncology
Modalities: small molecules
Industry: Biotech

Beyond the preview

Go deeper on Nuage Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuage Therapeutics.

Explore the full profile